Changes in the Updated 2016: W.H.O. Classification of the Myelodysplastic Syndromes (M.D.S.) and Related Myeloid Neoplasms

In comparison to the 2008 WHO “Blue Book” on Hematopoietic Neoplasms a small number of changes have been made in the Classification. In the lower risk patients RCMD-RS has been separated from RCMD to recognize the importance of the SF3B1 mutation.Often there has been confusion as to the degree of morphologic dysplasia and/or cytopenias to define some of the lower risk subtypes.In addition, the type of dysplasia or cytopenias are not always concordant.Therefore, it seems prudent to apply the more general term “MDS” with single or multiple lineage dysplasia.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 10, 2016 Category: Hematology Authors: John M. Bennett Source Type: research